US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

incretin peptides · obesity research literature · research use only

Incretin peptides for obesity: what the research literature actually studies.

Short answer: incretins are gut-derived hormones — principally GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — that are released after eating and amplify nutrient-stimulated insulin secretion, an effect known as the 'incretin effect' (oral glucose triggers a 2-3× larger insulin response than the same glucose given intravenously; Nauck MA, Meier JJ, Diabetes Obes Metab. 2018;20 Suppl 1:5-21, DOI 10.1111/dom.13129, PMID 29364588). 'Incretin peptides' in the obesity research literature refers to synthetic peptide agonists engineered to activate these incretin receptor systems — and increasingly the glucagon receptor as well. They fall into three designs by receptor-target count: GLP-1 mono-agonists (e.g. semaglutide), GIP/GLP-1 dual-agonists (e.g. tirzepatide), and GIP/GLP-1/glucagon triple-agonists (retatrutide, LY3437943). This is a class-overview hub framed strictly as investigational research science. The clinical-trial figures below are published science cited for context; they are NOT weight-loss, treatment, or efficacy claims for Titan's product, which is a research-use-only reagent, not for human or animal use, with no dosing guidance provided anywhere on this site. Not medical advice.

Retatrutide research reagent — $199.99 (in stock)All research peptides

What incretin peptides are: the biology in one paragraph

Incretins are hormones secreted by the gut in response to nutrient intake. The two classical incretins are GIP, released by K-cells in the upper small intestine, and GLP-1, released by L-cells in the lower gut. Together they produce the incretin effect — the enhanced insulin response to oral versus intravenous glucose. As reviewed by Nauck & Meier (Diabetes Obes Metab. 2018;20 Suppl 1:5-21, PMID 29364588), GIP is the primary driver of nutrient-stimulated insulin secretion in healthy individuals, while GLP-1 additionally suppresses glucagon and slows gastric emptying. 'Incretin peptides' as a drug/research class are synthetic peptides designed to activate these same receptors — the GIP receptor, the GLP-1 receptor, and, in the newest designs, the glucagon receptor — to study appetite, glycaemic, and energy-expenditure effects.

What is a triple agonist? →

Three receptor designs: mono, dual, and triple

The incretin-peptide class is organised by how many receptors a single molecule engages. Mono-agonists activate the GLP-1 receptor only (semaglutide). Dual-agonists (co-agonists) activate GIP + GLP-1 (tirzepatide). Triple-agonists activate GIP + GLP-1 + glucagon (retatrutide / LY3437943, first characterised by Coskun et al., Cell Metab. 2022;34:1234-1247, DOI 10.1016/j.cmet.2022.07.013, PMID 35985340). Each added receptor arm contributes distinct pharmacology: GLP-1 for appetite and glycaemic control, GIP for insulin secretion and adipose handling, glucagon for energy expenditure. This progression — one receptor, then two, then three — frames how the research literature has evolved over the past decade.

Compare the three across designs →

Retatrutide (triple-agonist): the largest published Phase 2 obesity finding

The triple-agonist retatrutide has the largest published human weight-change data in this class to date. In a Phase 2 double-blind, placebo-controlled randomised trial in 338 adults with obesity (Jastreboff AM et al., NEJM 2023;389:514-526, DOI 10.1056/NEJMoa2301972, PMID 37366315), least-squares mean body-weight change at 48 weeks was −24.2% (12 mg), −22.8% (8 mg), −17.1% (4 mg), and −8.7% (1 mg) versus −2.1% for placebo; ≥5% weight reduction occurred in 92% of participants at 4 mg and above. This is published Phase 2 clinical-trial science reported for research context only. It is not a statement about what Titan's research-use-only retatrutide reagent does in any organism, and no human-use, treatment, or dosing claim is made or implied.

How retatrutide works (mechanism) →

Class context: tirzepatide (dual) and semaglutide (mono)

The earlier incretin-peptide designs anchor the class context. Tirzepatide, a dual GIP/GLP-1 agonist, produced approximately −22.5% mean body-weight change at the 15 mg dose over 72 weeks in the Phase 3 SURMOUNT-1 trial (Jastreboff AM et al., NEJM 2022;387:205-216, DOI 10.1056/NEJMoa2206038). Semaglutide, a GLP-1 mono-agonist, produced approximately −14.9% at 2.4 mg/week over 68 weeks in the Phase 3 STEP 1 trial (Wilding JPH et al., NEJM 2021;384:989-1002, DOI 10.1056/NEJMoa2032183). These are approved pharmaceutical agents with published Phase 3 data, cited to show where the incretin class has been — not as comparisons to Titan's research reagents, which are investigational-compound reagents for laboratory use only.

Retatrutide vs tirzepatide →

The glucagon arm: why the newest incretin peptides add a third receptor

The frontier of the incretin-peptide class is the addition of glucagon-receptor (GCGR) agonism to the GIP/GLP-1 pair. Where GLP-1 and GIP mainly reduce appetite and improve insulin handling, glucagon-receptor agonism is studied for the opposite side of the energy-balance equation — energy expenditure. A peer-reviewed 2022 review (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037, DOI 10.3389/fendo.2022.868037) summarised evidence that glucagon-receptor activation stimulates thermogenesis in brown adipose tissue and has been associated with enhanced metabolic rate in humans. Combining appetite reduction (GLP-1/GIP) with potential energy-expenditure enhancement (glucagon) in one molecule is the mechanistic rationale behind the triple-agonist research direction. The relative contribution of each arm in humans remains an active area of investigation.

Peptides studied for fat loss →

Honest sourcing: RUO framing and lot-matched in-house release documentation

Titan states the honest posture plainly: incretin peptides such as retatrutide are investigational research compounds, and Titan's products are research-use-only reagents — not for human or animal consumption, and not represented as obesity treatments. On quality, incretin triple-agonist peptides are acylated (a fatty diacid gives the ~6-day half-life), so identity should be confirmed by mass spectrometry, not HPLC purity alone: the acylated species has a distinct molecular mass. Titan supplies lot-matched in-house release documentation (HPLC purity vs internal target + ESI-MS identity confirmation of the acylated species) on request. No third-party certificate of analysis is claimed — the verifiable edge is a real, lot-matched in-house release sheet, not a marketing 'lab-tested' badge.

Lot COA checklist for research peptides →

The detail, in plain terms

Incretin peptides for obesity research, at a glance.

Points below summarise the biology of incretins and the published research on the incretin-peptide class most studied in obesity trials. All figures are published clinical-trial science reproduced as research reference — not treatment, efficacy, or dosing claims for Titan's products. Research use only; not medical or human-use advice.

What is an incretin?
A gut hormone released after nutrient intake that amplifies insulin secretion. The two classical incretins are GIP (upper-gut K-cells) and GLP-1 (lower-gut L-cells).
The 'incretin effect'
Oral glucose triggers a 2-3× larger insulin response than the same glucose given IV. GIP is the primary driver in healthy humans. (Nauck & Meier, Diabetes Obes Metab. 2018;20 Suppl 1:5-21, PMID 29364588.)
Incretin-peptide class (research)
Synthetic peptide agonists of the GIP, GLP-1, and/or glucagon receptors — the most-studied compound class in published obesity trials.
Mono-agonist (GLP-1)
Semaglutide: ~−14.9% at 2.4 mg/week over 68 wk (STEP 1, Wilding et al., NEJM 2021;384:989-1002). Approved pharmaceutical.
Dual-agonist (GIP/GLP-1)
Tirzepatide: ~−22.5% at 15 mg over 72 wk (SURMOUNT-1, Jastreboff et al., NEJM 2022;387:205-216). Approved pharmaceutical.
Triple-agonist (GIP/GLP-1/glucagon)
Retatrutide (LY3437943): LS-mean −24.2% at 12 mg over 48 wk vs −2.1% placebo (Phase 2, Jastreboff et al., NEJM 2023;389:514-526, PMID 37366315). Investigational.
Glucagon arm rationale
GCGR agonism studied for thermogenesis in brown adipose tissue + enhanced metabolic rate — the energy-expenditure arm (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037).
Triagonist pharmacology source
Retatrutide/LY3437943 first characterised as a triple GCGR/GIPR/GLP-1R agonist by Coskun et al., Cell Metab. 2022;34:1234-1247 (PMID 35985340).
Identity check (acylated peptides)
Acyl-modified species must be confirmed by ESI-MS, not HPLC purity alone. Titan: lot-matched in-house HPLC + ESI-MS identity sheet on request. No third-party COA claimed.
Regulatory / RUO status
Retatrutide is investigational (no FDA approval). Titan's products are research-use-only reagents — not for human or animal use, not obesity treatments. No efficacy or dosing claim.

Questions researchers ask

Before you order.

What are incretin peptides?
Incretin peptides are synthetic peptide agonists that activate the receptor systems of the body's incretin hormones — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) — and, in the newest designs, the glucagon receptor as well. The natural incretins are gut hormones released after eating that amplify insulin secretion (the 'incretin effect'; Nauck & Meier, Diabetes Obes Metab. 2018;20 Suppl 1:5-21, PMID 29364588). In research, incretin peptides are the most-studied compound class in obesity trials and come in three designs: GLP-1 mono-agonists, GIP/GLP-1 dual-agonists, and GIP/GLP-1/glucagon triple-agonists. Titan supplies these strictly as research-use-only reagents, not for human use.
Which incretin peptides are studied for obesity, and what did the trials show?
Three designs dominate the published obesity research. Semaglutide (GLP-1 mono-agonist) produced ~−14.9% mean weight change at 2.4 mg/week over 68 weeks (STEP 1, NEJM 2021). Tirzepatide (GIP/GLP-1 dual-agonist) produced ~−22.5% at 15 mg over 72 weeks (SURMOUNT-1, NEJM 2022). Retatrutide (GIP/GLP-1/glucagon triple-agonist) produced −24.2% LS-mean at 12 mg over 48 weeks versus −2.1% placebo in its Phase 2 trial (Jastreboff et al., NEJM 2023;389:514-526, PMID 37366315). These are published clinical-trial results for the drug class, cited as research context only — not claims about Titan's research-use-only reagents, which carry no efficacy, treatment, or dosing claim.
How do incretin peptides work in obesity research?
Each receptor arm contributes a distinct studied effect. GLP-1 receptor agonism suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. GIP receptor agonism — the dominant driver of the natural incretin effect in humans — augments insulin secretion and enhances adipose-tissue insulin sensitivity and lipid handling. The glucagon receptor arm (present only in triple-agonists) is studied for increasing energy expenditure via thermogenesis in brown adipose tissue (Conceição-Furber et al., Front. Endocrinol. 2022;13:868037). Multi-receptor designs aim to combine reduced caloric intake with potentially increased energy expenditure. This describes published research mechanisms, not effects claimed for any Titan product.
Are incretin peptides approved obesity treatments?
Some incretin peptides are approved pharmaceuticals (the GLP-1 mono-agonist semaglutide and the GIP/GLP-1 dual-agonist tirzepatide), but the triple-agonist retatrutide (LY3437943) remains investigational as of 2026 — only Phase 2 data have been published, with Phase 3 ongoing. Titan Peptide Lab does not sell approved medicines and does not represent any product as an obesity treatment. Titan's incretin peptides, including retatrutide, are supplied strictly as research-use-only reagents for in-vitro laboratory use — not for human or animal administration. The trial data on this page is published science for context, not a claim about Titan's products, and not medical advice.
How do I verify an incretin peptide reagent is the correct compound?
Incretin peptides used in the triple-agonist class (such as retatrutide) are acylated — a fatty diacid chain is conjugated to the backbone to produce the long half-life. A simple HPLC purity percentage tells you the proportion of the major peak but not whether that peak is the correctly acylated molecule. Identity should be confirmed by mass spectrometry, because the acylated species has a distinct molecular weight from unmodified peptide. Titan provides lot-matched, in-house release documentation (HPLC purity vs internal target + ESI-MS identity of the acylated species) on request. No third-party certificate of analysis is claimed — the honest, verifiable edge is a real lot-matched in-house release sheet.

Related reading

Before you check out.